Industries · Cell & Gene Therapy
Cell & Gene Therapy
Multi-omics characterisation of engineered cells: identity, potency, heterogeneity and genomic integrity.
Industries · Cell & Gene Therapy
Multi-omics characterisation of engineered cells: identity, potency, heterogeneity and genomic integrity.
An engineered cell has to be characterised at more than one molecular level. GenXMap combines genomic, transcriptomic and proteomic profiling with targeted sequencing and single-cell approaches to determine what an engineered product is, how it behaves, and how consistently that profile holds across development and manufacturing.
A designed programme rather than an analysis order: which molecular layers answer the development question, which reference the construct requires, and which comparisons separate biological variation from process variation. Those are settled before sampling, not after.
WGS, WES and targeted sequencing at complementary levels of resolution, from broad genomic characterisation to focused validation of selected variants or engineered regions.
The analytical reference is built for the construct, including vector sequences, backbone elements, promoters and edited regions. A standard human reference will not place reads that belong to the construct, which is why the reference comes first.
Vector integration sites identified and their distribution characterised across the population.
Bulk RNA-seq for construct expression and for the host-cell programmes that engineering alters. Where the question is which cells carry the change rather than whether the population does, single-cell analysis resolves it.
Mass-spectrometry profiling, including TIMS-TOF workflows, for the protein-level state of the engineered product.
The same analytical framework applied across batches, passages and process conditions, which is what separates expected biological variation from an emerging subpopulation or a process-associated drift.
DNA gives the genomic context, RNA the transcriptional state, protein the downstream phenotype, and single-cell data the cellular origin of each signal. They are integrated around the development question rather than reported as separate analyses.
Study design, sample information, methods, tool versions, parameters, QC metrics and statistical results. Every analytical decision documented and traceable, built to be reviewed, challenged and reproduced by an independent team.
Engineering, expansion, passage, process development, final product. Measuring only the final product hides changes in population composition, expression and genomic profile that occurred along the way, and those changes are usually what a comparability question turns on.
GenXMap designs the analytical strategy around the milestone, whether that is process development, potency assessment, comparability or tech transfer, defining the samples, layers, comparisons and validation steps before the study begins.
The laboratory work can run on OMICS4, GenXMap’s platform site, or the analysis can start with data generated elsewhere. Existing WGS, WES, targeted sequencing, RNA-seq, proteomic or single-cell datasets can be analysed on their own or integrated within the same framework.
Data generated elsewhere often arrives without the metadata the analysis needs. We tell you what can be concluded from it before any work starts, rather than after.
What determines the analysis is the biological question, the study design and the available metadata.
Book the platforms on OMICS4Case studies for this industry are in preparation: get in touch to discuss a project directly.
Tell us the product, the stage and the milestone.